These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 8638281)
1. Immunotoxicity assessment of biotechnology products: a regulatory point of view. Cavagnaro JA Toxicology; 1995 Dec; 105(1):1-6. PubMed ID: 8638281 [No Abstract] [Full Text] [Related]
3. Immunotoxicity testing applied to direct food and colour additives: US FDA 'Redbook II' Guidelines. Hinton DM Hum Exp Toxicol; 1995 Jan; 14(1):143-5. PubMed ID: 7748605 [No Abstract] [Full Text] [Related]
4. [Immunotoxicity and pathogenicity of substances]. van den Tweel JG Ned Tijdschr Geneeskd; 1992 Oct; 136(40):1949-51. PubMed ID: 1407175 [No Abstract] [Full Text] [Related]
7. US FDA "Redbook II" immunotoxicity testing guidelines and research in immunotoxicity evaluations of food chemicals and new food proteins. Hinton DM Toxicol Pathol; 2000; 28(3):467-78. PubMed ID: 10862567 [TBL] [Abstract][Full Text] [Related]
8. Blood products part of FDA xenotransplant plan. Fox JL Nat Biotechnol; 2000 Mar; 18(3):258. PubMed ID: 10700130 [No Abstract] [Full Text] [Related]
9. Comparison of two guidelines on immunotoxicity testing of medicinal products. Dujmović IH Arh Hig Rada Toksikol; 2005 Sep; 56(3):265-8. PubMed ID: 16180612 [TBL] [Abstract][Full Text] [Related]
11. International Conference on Harmonisation; guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability--FDA. Notice. Fed Regist; 1998 Sep; 63(185):51074-84. PubMed ID: 10185809 [TBL] [Abstract][Full Text] [Related]
12. Target organs and systems: methodologies to assess immune system function. Karol MH Environ Health Perspect; 1998 Apr; 106 Suppl 2(Suppl 2):533-40. PubMed ID: 9599701 [TBL] [Abstract][Full Text] [Related]
13. Safety evaluation of biological and biotechnology-derived medicines. Dayan AD Toxicology; 1995 Dec; 105(1):59-68. PubMed ID: 8638284 [TBL] [Abstract][Full Text] [Related]
14. A Regulatory Perspective on Testing of Biological Activity of Complex Biologics. Saldanha M; Dandekar P; Jain R Trends Biotechnol; 2018 Mar; 36(3):231-234. PubMed ID: 29310842 [TBL] [Abstract][Full Text] [Related]
15. NK-cell activity in immunotoxicity drug evaluation. Cederbrant K; Marcusson-Ståhl M; Condevaux F; Descotes J Toxicology; 2003 Apr; 185(3):241-50. PubMed ID: 12581699 [TBL] [Abstract][Full Text] [Related]
16. Histopathologic approaches to detect changes indicative of immunotoxicity. Kuper CF; Harleman JH; Richter-Reichelm HB; Vos JG Toxicol Pathol; 2000; 28(3):454-66. PubMed ID: 10862566 [TBL] [Abstract][Full Text] [Related]
17. Compliance with Good Manufacturing Practices for facilities engaged in vector production, cell isolation, and genetic manipulations. Steel MP; Roessler BJ Curr Opin Biotechnol; 1999 Jun; 10(3):295-7. PubMed ID: 10361080 [No Abstract] [Full Text] [Related]
18. A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements. Giannakou C; Park MV; de Jong WH; van Loveren H; Vandebriel RJ; Geertsma RE Int J Nanomedicine; 2016; 11():2935-52. PubMed ID: 27382281 [TBL] [Abstract][Full Text] [Related]
19. Nanotechnology and the U.S. Food and Drug Administration. Marlowe DE Stand News; 2005 Jul; 33(7):29-31. PubMed ID: 16237872 [No Abstract] [Full Text] [Related]